RELATIONSHIP BETWEEN SERUM OC AND SCTX WITH BONE MINERAL DENSITY IN PREDICTING BONE LOSS AND TREATING FOR POSTMENOPAUSAL OSTEOPOROSIS WOMEN OVER 45 YEARS OLD WITH FOSAMAX PLUS THERAPY

Abstract

Backgrounds: Serum OC and ssCTX are correlated with BMD and have early changes under antiresorptive therapies. This study was aimed to find correlations between serum OC, sCTX and BMD changes in women over 45 and evaluated early changes of the two markers in postmenopausal osteoporotic women with Fosamax plus therapy. Materials and Methods: Cross-sectional and prospective study. 142 women over 45 were tested for serum OC and sCTX and determined BMD at lumbar spine and femur neck. 37 postmenopausal osteoporotic women of the group were treated with Fosamax plus therapy. Results: OC and sCTX showed negative correlation with BMD of lumbar spine and femur neck in all of women over 45. The correlation between sCTX and BMD of femur neck was not significant. The lowest values of OC and sCTX to predict bone loss in non-osteoporotic women were 14.46ng/ml (ss = 76.1%, sp = 40%) and 396.25pg/ml (ss = 66%, sp = 52%). The decreasing rates of serum OC and sCTX after 3 and 6 months with Fosamax plus therapy were 41.6%, 55% (p ˂ 0.0001) and 78.3%, 72% (p ˂ 0.0001), respectively. Slow increasing rates of BMD at two sites were 4.2% (p ˂ 0.001) and 3.6% (p ˃ 0.05), irrespectively. Conclusions: OC and sCTX were inversely correlated to BMD of lumbar spine and femur neck in all of women over 45. The lowest values of OC and sCTX to predict bone loss in non-osteoporotic women were 14.46ng/ml and 396.25pg/ml. Serum OC và sCTX decreased early in comparision to BMD improvement in postmenopausal osteoporotic women with Fosamax plus therapy. Key words: oC, sCTX, postmenopausal osteoporotic women, Fosamax plus